<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01884935</url>
  </required_header>
  <id_info>
    <org_study_id>101MS328</org_study_id>
    <secondary_id>2012-005082-13</secondary_id>
    <nct_id>NCT01884935</nct_id>
  </id_info>
  <brief_title>PK and PD Study of Natalizumab in Pediatric Subjects With RRMS</brief_title>
  <official_title>A Phase 1, Multicenter, Open-Label, Single-Arm, Multiple Dose Study to Evaluate the the Pharmacokinetics and Pharmacodynamics of Natalizumab in Pediatric Subjects With Relapsing Remitting Multiple Sclerosis (RMS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biogen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biogen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to determine the pharmacokinetic (PK) profile of
      multiple doses of natalizumab in pediatric subjects with relapsing-remitting multiple
      sclerosis (RRMS). The secondary objectives are as follows: to characterize the
      pharmacodynamic (PD) profile of natalizumab (as defined by α4 integrin binding) and to
      explore the safety and tolerability of multiple doses of natalizumab in the pediatric
      population.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>predose (trough) concentrations from multiple dosing (Cpredose)</measure>
    <time_frame>Up to week 16</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>maximum plasma concentration (Cmax)</measure>
    <time_frame>Up to Week 16</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>time to maximum plasma concentration (Tmax)</measure>
    <time_frame>Up to Week 16</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>area under the plasma concentration curve from time of first dose to infinity (AUCinf)</measure>
    <time_frame>Up to Week 16</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>apparent clearance (Cl/F)</measure>
    <time_frame>Up to Week 16</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>volume of distribution</measure>
    <time_frame>Up to Week 16</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>elimination half-life (t1/2)</measure>
    <time_frame>Up to Week 16</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>the average and minimum saturation values of α4 integrin over the dosing interval</measure>
    <time_frame>Up to Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of serious adverse events (SAEs), infusion and hypersensitivity reactions, and other AEs</measure>
    <time_frame>Up to Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the presence of anti-natalizumab antibodies</measure>
    <time_frame>Up to Week 16</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Relapsing-Remitting Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Natalizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>300 mg intravenously (IV) every 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Natalizumab</intervention_name>
    <description>As specified in the treatment arm</description>
    <arm_group_label>Natalizumab</arm_group_label>
    <other_name>Tysabri</other_name>
    <other_name>BG00002</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

        - Rapidly evolving severe relapsing remitting multiple sclerosis, defined by 2 or more
        disabling relapses in 1 year, and with 1 or more gadolinium-enhancing lesions on brain MRI
        or a significant increase in T2 lesion load, as compared to a previous recent magnetic
        resonance imaging (MRI)

        Key Exclusion Criteria:

          -  History of, or abnormal laboratory values indicative of, significant medical,
             neurologic (other than MS), or psychiatric disorders that might preclude participation
             in the study in the opinion of the Investigator.

          -  Prior natalizumab therapy.

        NOTE: Other protocol defined Inclusion/Exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Biogen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cefalu</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gallarate</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Padua</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rome</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <link>
    <url>https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-005082-13/results</url>
    <description>EudraCT Tabulated Result</description>
  </link>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 20, 2013</study_first_submitted>
  <study_first_submitted_qc>June 20, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 24, 2013</study_first_posted>
  <last_update_submitted>June 21, 2016</last_update_submitted>
  <last_update_submitted_qc>June 21, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 23, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pediatric</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Natalizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

